Alector. has been granted a patent for transgenic non-human animals engineered to express multiple human genes related to the Siglec immune system. The patent includes methods for screening candidate agents that interact with these genes, potentially aiding in the development of new therapeutic agents. GlobalData’s report on Alector gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Alector, Personalized cancer vaccines was a key innovation area identified from patents. Alector's grant share as of June 2024 was 20%. Grant share is based on the ratio of number of grants to total number of patents.
Transgenic animals for screening human gene-modulating agents
The granted patent US12004494B2 outlines a method for screening candidate agents using a transgenic mouse model that incorporates multiple human genes, specifically from the Siglec family and CD33. The method involves administering one or more candidate agents to these genetically modified mice, which express the selected human genes in various immune cell types, including myeloid cells, natural killer (NK) cells, and T cells. The primary objective is to assess whether these agents can bind to or modulate the function of the human genes, thereby influencing immune responses. The patent details various potential effects of the candidate agents, including inhibition of immune cell activities, modulation of inflammatory cytokine expression, and alterations in immune cell proliferation and migration.
Additionally, the patent specifies that the transgenic mice may be used to model various diseases, disorders, or injuries, such as cancer, autoimmune diseases, and neurodegenerative conditions. The screening method aims to identify agents that can reduce or eliminate symptoms associated with these conditions. The claims further elaborate on the specific immune functions that may be affected by the candidate agents, including the suppression of pro-inflammatory cytokines, enhancement of anti-inflammatory responses, and modulation of immune cell interactions. The comprehensive nature of the claims highlights the potential for these methods to contribute to the development of therapeutic agents targeting a wide range of diseases by leveraging the humanized immune system of the transgenic mouse model.
To know more about GlobalData’s detailed insights on Alector, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
